ck1

CK1-IN-3 is casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases.

IC261 (SU-5607) is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.

D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).

CK1-IN-1 (PUN51207) is a casein kinase 1 (CK1) inhibitor. CK1-IN-1 has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.

CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with IC50 values of 123, 19.8, 26.8, and 74.3 nM for CK1a, CK1d, CK1e, and p38a, respectively, and is used in DUX4 overexpression-associated diseases, such as muscular dystrophy.

CK1-IN-4 (Compound 59) is an inhibitor of casein kinase CK1δ with an IC50 of 2.74 μM. It exhibits neuroprotective activity in SH-SY5Y cells treated with Ethacrynic acid.

CK1-IN-2 (compound Nr.4) hydrochloride is an effective inhibitor of CK1, exhibiting inhibitory IC50 values of 123 nM, 19.8 nM, 26.8 nM, and 74.3 nM against CK1a, CK1d, CK1e, and p38a respectively.

CK1δ CK1ε ligand-1 is a ligand of CK1δ CK1ε and can serve as a target protein ligand for the synthesis of the CK1 PROTAC degrader AH078.

CK1δ-IN-10 (Compound 85) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ (CSNKID), with an IC50 value of 0.255 μM.

CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.

CK1tide serves as a substrate for Casein Kinase 1 (CK1), allowing for the assessment of CK1's catalytic activity in vitro by determining its ability to phosphorylate CK1tide.

Compound STOCK1N-54584 is a natural product that can be used as a reference standard.

dCK1α-2 is an orally effective CK1α molecular glue (Molecular Glue) degrader that targets p53 pathway-related targets. It demonstrates antitumor efficacy in mouse models by enhancing the expression of p53-related genes.

CK1δ-IN-3 (compound 376) is an inhibitor of casein kinase 1δ (CK1δ). It is useful for research in neurodegenerative diseases.

CK1δ-IN-6 (Compound 303) is an inhibitor of Casein kinase 1δ, with potential applications in Alzheimer's disease research.

CK1δ-IN-7 (Compound 488) is an inhibitor of casein kinase 1δ (CK1δ).

CK1δ-IN-5 (Compound 24) is an inhibitor of casein kinase 1δ (CK1δ) and can be used in the study of neurodegenerative diseases.

CK1δ-IN-8 (Compound 429) is a CK1δ inhibitor suitable for Alzheimer's disease research.

p38αMAPK CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.185 µM and 0.089 µM, respectively.